Curated News
By: NewsRamp Editorial Staff
August 22, 2025
Calidi Biotherapeutics Secures $6.9M in Public Offering for Cancer Therapy Development
TLDR
- Calidi Biotherapeutics raised $6.9 million, providing investors early access to its innovative Redtail platform targeting metastatic cancers with high unmet medical need.
- Calidi sold 1.9 million common stock units at $2.00 each and 1.5 million pre-funded warrant units at $1.999, with warrants exercisable at $2.00 for five years.
- Calidi's funding advances therapies that could deliver genetic medicines to metastatic cancer sites, potentially improving outcomes for patients with limited treatment options.
- Calidi's engineered oncolytic virus platform shields therapies from immune clearance to target distant tumors, representing a novel approach in immuno-oncology.
Impact - Why it Matters
This development matters because Calidi Biotherapeutics is advancing novel cancer treatments that could revolutionize how metastatic cancers are treated. Their Redtail platform technology addresses a critical challenge in oncology - effectively delivering therapies to distant tumor sites while avoiding immune system detection. For patients with aggressive cancers like non-small cell lung cancer and ovarian cancer, this approach could mean more effective treatments with potentially fewer side effects. The successful funding round indicates investor confidence in their technology and accelerates the timeline for bringing these innovative therapies to clinical trials and eventually to patients who desperately need better treatment options.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company pioneering targeted therapies for delivering genetic medicines to distal disease sites, has successfully closed an underwritten public offering that generated $6.9 million in gross proceeds. The company sold 1,922,764 common stock units at $2.00 each and 1,528,000 pre-funded warrant units at $1.999 each, with Ladenburg Thalmann & Co. Inc. acting as sole book-running manager and Laidlaw & Company (U.K.) Ltd. serving as co-manager. This financial boost will support Calidi's innovative Redtail platform, which features engineered enveloped oncolytic viruses designed for systemic delivery to metastatic cancer sites while evading immune clearance.
The company's lead candidate from the Redtail platform is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs. Additionally, Calidi is developing protected virotherapies for intratumoral and localized administration, focusing on injectable cancer indications. The news was distributed through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio that provides extensive media reach and corporate communications solutions for innovative small-cap and mid-cap companies with significant growth potential.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics Secures $6.9M in Public Offering for Cancer Therapy Development
